Scholarship applications for Cohort 14 of #VCUniversity are now open! Created by Venture Forward, the scholarship covers tuition, office hours and a curated mentorship component that we’re proud to be a part of. Apply for the life sciences track by 6/23: bit.ly/3NjNXMY

Proud to share the news that XinThera was acquired by Gilead Sciences today. We were the founding investor, seeing the potential in their approach to cancer and inflammatory diseases through drugs that block the proteins PARP1 or MK2. endpts.com/gilead-acquire…

Aspiring VCs from underrepresented backgrounds: Venture Forward is offering full scholarships to Cohort 13 (June 2023) of #VCUniversity , including course tuition, office hours, and dedicated mentorship. Learn more + apply by Friday, 3/24: venturecapitaluniversity.com/scholarship/on…

Introducing our blog series featuring chats with our team members. Check out the conversation with Managing Director Michael Rome on the state of healthcare & his expert take on shaping trends & challenges. medium.com/foresite-capit…

Meet the Cohort 12 scholarship recipients!

New podcast with the head of medical affairs at our portfolio company Mirvie on the state of maternal care and what is needed for meaningful change. The team at Mirvie has set out to identify risks months before symptoms occur.

Understanding who is at risk for pregnancy complications is the first step toward personalized preventive care. We are proud of the work being done to address this by our portfolio company Mirvie. Read Alison Cowan, M.D.’s interview with CNBC to learn more.

We're excited to support FOLX HEALTH as they scale their health and wellness platform designed uniquely for the LGBTQIA+ community. Thank you to Andrew Mendez and @techcrunch for this coverage.

What do #PregnancyHealth experts say needs to change to reduce pregnancy-related death? Read Alison Cowan, M.D.’s perspective on the opportunities for prevention and the importance of patient education and empowerment in CNBC: cnbc.com/2022/10/03/cdc…

We're excited to be working with this precision oncology team to bring better, more targeted therapies to people with hard-to-treat cancers.

Cohort 11 looks solid! These individuals in the life sciences track will be shaping the future of our industry, and we couldn't be more proud to support this program with our friends at Venture Forward.

Apply by June 24th for a full scholarship to #VCUniversity and the new life science track for aspiring life science investors from underrepresented backgrounds.

This is a really impressive cohort, and we're so proud of our work with Venture Forward and our fellow supporting sponsors. It's small steps like these that will help bring about a more diverse and inclusive future for our industry.

Our managing director Michael Rome shares his thoughts on the Affinivax acquisition by GSK in our latest blog post: foresitecapital.com/blog/thoughts-…

Congratulations to Foresite Capital Fellow Xinhong Chen for his publication in Neuron on non-invasive gene delivery. We're so proud of his accomplishments!

cell.com/neuron/fulltex…

Congratulations to our portfolio company Affinivax on their acquisition by GSK! A great move to advance their vaccines that combat novel and resistant infectious diseases that currently have no effective immunization strategies.
wsj.com/articles/gsk-b…

Congratulations to the team at Remix Therapeutics on this new funding and their recent J&J deal. Really proud to be supporting their work to develop novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

So proud to support the team at Mirvie in their quest to develop non-invasive diagnostic tools to help predict the risk of pregnancy conditions like preeclampsia and premature birth. forbes.com/sites/katiejen…

Great news out of Foresite Labs, promoting two key employees into new roles. We are so proud of the progress at Labs in such a short time.

Congratulations to Aaron Ring from our portfolio company Seranova Bio Bio for his inclusion in this Endpoints News list of 20 under 40. 'Everything is about momentum' -- we agree and we're thrilled to be working together.